Methotrexate; Evaluation of the effects on reproduction, recommendation for classification

In the present report, the Health Council of the Netherlands reviewed methotrexate. Methotrexate is used to induce (i.e. non-surgical) abortions in very early pregnancies and to treat ectopic pregnancies, various cancers, rheumatoid arthritis and other inflammatory rheumatic disorders, and psoriasis. This report is part of a series, in which the Health Council evaluates the effects of substances on reproduction, at the request of the Minister of Social Affairs and Employment.

Committee

• A.H. Piersma, Professor of Reproductive and Developmental Toxicology, Utrecht University, Utrecht; National Institute of Public Health and the Environment, Bilthoven, chairman
• D. Lindhout, Professor of Medical Genetics, Paediatrician (not practizing), Clinical Geneticist, University Medical Centre, Utrecht
• N. Roeleveld, Reproductive Epidemiologist, Radboud University Nijmegen Medical Centre, Nijmegen
• J.G. Theuns-van Vliet, Reproductive Toxicologist, TNO Triskelion BV, Zeist
• D.H. Waalkens-Berendsen, Reproductive Toxicologist, Zeist
• P.J.J.M. Weterings, Toxicologist, Weterings Consultancy BV, Rosmalen
• A.S.A.M. van der Burght, Health Council of the Netherlands, Den Haag, scientific secretary
• J.T.J. Stouten, Health Council of the Netherlands, Den Haag, scientific secretary